Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEON AEON Biopharma	$0.78 -2.5%	$0.79	$0.38 ▼ $115.57	$8.82M	0.71	1.69 million shs	49,940 shs
GNPX GENPREX	$0.22 -4.1%	$0.26	$0.20 ▼ $3.97	$7.46M	-0.53	1.06 million shs	857,569 shs
OBSV ObsEva		$0.00	$0.08 ▼ $2.14	$7.94M	0.68	8.94 million shs	300 shs
SXTP 60 Degrees Pharmaceuticals	$1.31 -3.0%	$1.92	$1.24 ▼ $12.70	$1.99M	2.71	225,749 shs	148,261 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEON AEON Biopharma	-2.50%	+9.35%	-2.38%	+56.00%	-98.93%
GNPX GENPREX	-4.09%	-2.44%	-27.17%	-12.62%	-70.42%
OBSV ObsEva	0.00%	0.00%	-75.00%	-75.00%	-75.00%
SXTP 60 Degrees Pharmaceuticals	-2.96%	-0.76%	-25.14%	-46.96%	-80.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AEON AEON Biopharma	3.4375 of 5 stars	3.5	5.0	0.0	0.0	0.6	1.7	1.9
GNPX GENPREX	1.489 of 5 stars	0.0	3.0	0.0	4.7	2.5	0.0	0.6
OBSV ObsEva	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	2.8268 of 5 stars	3.3	4.0	0.0	0.0	1.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEON AEON Biopharma	3.00	Buy	$360.00	46,053.85% Upside
GNPX GENPREX	0.00	N/A	N/A	N/A
OBSV ObsEva	0.00	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	2.50	Moderate Buy	$7.00	434.35% Upside

Current Analyst Ratings Breakdown

Latest SXTP, OBSV, AEON, and GNPX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
7/29/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
7/12/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/27/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/11/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/2/2025	SXTP 60 Degrees Pharmaceuticals	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.80 ➝ $7.00
5/24/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEON AEON Biopharma	N/A	N/A	N/A	N/A	($4.12) per share	N/A
GNPX GENPREX	N/A	N/A	N/A	N/A	$0.15 per share	N/A
OBSV ObsEva	N/A	N/A	N/A	N/A	$0.41 per share	N/A
SXTP 60 Degrees Pharmaceuticals	$300K	6.42	N/A	N/A	($6.38) per share	-0.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEON AEON Biopharma	-$36.63M	-$6.08	4.33	N/A	N/A	N/A	N/A	-994.63%	N/A
GNPX GENPREX	-$21.11M	N/A	0.00	N/A	N/A	N/A	-664.65%	-370.18%	8/15/2025 (Estimated)
OBSV ObsEva	-$58.38M	-$0.92	N/A	N/A	N/A	N/A	-416.36%	-92.01%	N/A
SXTP 60 Degrees Pharmaceuticals	-$7.95M	-$50.41	N/A	N/A	N/A	-976.86%	N/A	-122.33%	N/A

Latest SXTP, OBSV, AEON, and GNPX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	GNPX GENPREX	-$0.71	-$0.17	+$0.54	-$0.17	N/A	N/A
8/13/2025	Q2 2025	SXTP 60 Degrees Pharmaceuticals	-$1.24	-$1.25	-$0.01	-$1.25	$0.32 million	$0.31 million
5/15/2025	Q1 2025	SXTP 60 Degrees Pharmaceuticals	-$1.31	-$1.56	-$0.25	-$1.56	$0.15 million	$0.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEON AEON Biopharma	N/A	N/A	N/A	N/A	N/A
GNPX GENPREX	N/A	N/A	N/A	N/A	N/A
OBSV ObsEva	N/A	N/A	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEON AEON Biopharma	N/A	0.22	0.22
GNPX GENPREX	N/A	1.94	1.94
OBSV ObsEva	N/A	0.61	0.61
SXTP 60 Degrees Pharmaceuticals	N/A	3.14	2.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEON AEON Biopharma	22.78%
GNPX GENPREX	14.05%
OBSV ObsEva	17.52%
SXTP 60 Degrees Pharmaceuticals	7.96%

Insider Ownership

Company	Insider Ownership
AEON AEON Biopharma	0.86%
GNPX GENPREX	0.44%
OBSV ObsEva	14.40%
SXTP 60 Degrees Pharmaceuticals	10.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEON AEON Biopharma	5	11.31 million	74.37 million	Not Optionable
GNPX GENPREX	20	33.15 million	33.00 million	No Data
OBSV ObsEva	50	77.97 million	66.74 million	Not Optionable
SXTP 60 Degrees Pharmaceuticals	3	1.47 million	1.32 million	Not Optionable

SXTP, OBSV, AEON, and GNPX Headlines

Recent News About These Companies

60 Degrees Pharmaceuticals' (SXTP) "Sell (E+)" Rating Reiterated at Weiss Ratings

2 hours ago | americanbankingnews.com

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

August 13 at 4:19 PM | globenewswire.com

60 Degrees Pharmaceuticals (SXTP) to Release Quarterly Earnings on Wednesday

August 12 at 2:11 AM | americanbankingnews.com

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

July 16, 2025 | globenewswire.com

60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025

July 15, 2025 | finanznachrichten.de

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration ...

July 15, 2025 | finanznachrichten.de

60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

July 15, 2025 | globenewswire.com

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODAÂ® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

July 15, 2025 | globenewswire.com

SXTP - 60 Degrees Pharmaceuticals Inc Valuation - Morningstar

July 3, 2025 | morningstar.comM

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Director Cheryl Xu Acquires 5,000 Shares

June 6, 2025 | insidertrades.com

60 Degrees Pharmaceuticals Reports Significant Discrepancy in Babesiosis Case Estimates and Plans for New Drug Application in 2026

June 5, 2025 | nasdaq.com

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

June 4, 2025 | globenewswire.com

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

June 3, 2025 | globenewswire.com

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

May 15, 2025 | globenewswire.com

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

April 22, 2025 | globenewswire.com

Why 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday?

April 10, 2025 | insidermonkey.com

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

April 10, 2025 | globenewswire.com

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

April 10, 2025 | globenewswire.com

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

April 8, 2025 | globenewswire.com

60 Degrees Pharmaceuticals, Inc.

April 4, 2025 | uk.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTP, OBSV, AEON, and GNPX Company Descriptions

AEON Biopharma NASDAQ:AEON

$0.78 -0.02 (-2.50%)

Closing price 08/14/2025 03:59 PM Eastern

Extended Trading

$0.75 -0.03 (-3.33%)

As of 04:33 AM Eastern

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

GENPREX NASDAQ:GNPX

$0.22 -0.01 (-4.09%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$0.23 +0.01 (+5.09%)

As of 04:35 AM Eastern

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

ObsEva NASDAQ:OBSV

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

60 Degrees Pharmaceuticals NASDAQ:SXTP

$1.31 -0.04 (-2.96%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.32 +0.01 (+0.46%)

As of 04:34 AM Eastern

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time